MRI/超声融合引导经会阴与经直肠前列腺穿刺活检的系统综述
本系统综述比较MRI/超声融合引导经会阴穿刺(MRI-TPB)与经直肠穿刺(MRI-TRUSB)对前列腺癌的检出率和并发症。纳入5项定性、2项定量研究,每患者分析显示MRI-TPB对临床显著前列腺癌检出率显著更高(RR 1.28,95%CI 1.03-1.60,p=0.03),前部病灶检出率亦更高(RR 2.46,95%CI 1.22-4.98,p=0.01),且并发症更低(OR 2.56,95%CI 1.14-5.56,p<0.05)。所有结局证据确定性均为极低。
要点
- MRI-TPB对临床显著前列腺癌的每患者检出率显著高于MRI-TRUSB(RR 1.28,p=0.03)。
- MRI-TPB对前部病灶的临床显著前列腺癌检出率显著更高(RR 2.46,p=0.01)。
- MRI-TPB并发症发生率更低(OR 2.56,p<0.05),但所有结局证据确定性极低。
核心结论
- MRI-TPB对临床显著前列腺癌、前部肿瘤检出率更高且感染并发症更少,但证据质量极低。
研究设计与样本
- 系统综述,检索PubMed、Scopus、EMBASE和CENTRAL,纳入比较MRI-TRUSB与MRI-TPB的随机对照试验和观察性研究。
- 共检索到3608项研究,5项纳入定性合成,2项纳入定量合成。
主要发现
- 每患者合并分析显示,MRI-TPB对临床显著前列腺癌检出率显著高于MRI-TRUSB(RR 1.28,95%CI 1.03-1.60,p=0.03)。
- 每病灶分析显示,MRI-TPB对前部临床显著前列腺癌检出率显著更高(RR 2.46,95%CI 1.22-4.98,p=0.01)。
- 每病灶分析中,MRI-TPB与MRI-TRUSB总体癌检出率分别为75%和81.6%(p=0.53),临床显著前列腺癌检出率分别为65.7%和75.5%(p=0.40)。
- MRI-TPB并发症发生率更低(OR 2.56,95%CI 1.14-5.56,p<0.05)。
关键数值与推荐
- GRADE评价所有结局指标的证据确定性均为极低。
临床怎么用
- 基于极低确定性证据,MRI-TPB在临床显著前列腺癌和前部肿瘤检出及降低并发症方面可能更优。
- 作者建议研究人员和临床医生采用务实方法,维护前瞻性数据库、对MRI-TPB方法进行内部审计,并与历史MRI-TRUSB队列比较。
局限性
- 比较MRI-TPB与MRI-TRUSB的高质量证据匮乏。
- 所有结局的证据确定性均为极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Magnetic resonance imaging (MRI)-targeted biopsies have changed the dogma in prostate cancer diagnosis. Biopsies can be performed either transrectally (MRI-guided and transrectal ultrasound fusion transrectal biopsy [MRI-TRUSB]) or transperineally (MRI-guided and transrectal ultrasound fusion transperineal biopsy [MRI-TPB]). OBJECTIVE: To evaluate the detection and complication rates of MRI-TRUSB and MRI-TPB. EVIDENCE ACQUISITION: We performed a literature search in PubMed, Scopus, EMBASE, and CENTRAL, and selected randomized controlled trials (RCTs) and observational studies comparing MRI-TRUSB versus MRI-TPB. EVIDENCE SYNTHESIS: Our search identified 3608 studies; we included five in the qualitative and two in the quantitative synthesis. On per-patient pooled analysis for clinically significant prostate cancer (csPCa), MRI-TPB detection rates were significantly higher (relative risk 1.28 [95% confidence interval {CI} 1.03-1.60], p = 0.03). On a per-lesion analysis, MRI-TPB anterior csPCa detection rates were statistically significantly higher (relative risk 2.46 [95% CI 1.22-4.98], p = 0.01). On a per-lesion analysis, MRI-TPB and MRI-TRUSB overall cancer detection rates were 75% and 81.6% (p= 0.53), and csPCa detection rates were 65.7% and 75.5% (p = 0.40), respectively. MRI-TPB had lower complication rates (odds ratio 2.56 [95% CI 1.14-5.56, p < 0.05]). On Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evaluation, we rated all outcomes as "very low" certainty of the evidence for all outcome measures. CONCLUSIONS: This review highlights the paucity of good-quality evidence comparing MRI-TPB and MRI-TRUSB. MRI-TPB achieves better detection for csPCa, anterior tumors, and lower infective complications. While RCTs are the highest quality of evidence that can address existing evidence limitations, there are concerns regarding infective complications associated with the MRI-TRUSB. Therefore, the authors propose that researchers and clinicians adopt a pragmatic approach by maintaining prospective databases, internal auditing of the MRI-TPB approach, and comparing these data with historical MRI-TRUSB cohorts. PATIENT SUMMARY: We looked at the outcomes by comparing magnetic resonance imaging (MRI)-guided and transrectal ultrasound fusion transrectal biopsy with MRI-guided and transrectal ultrasound fusion transperineal biopsy (TPB). The analysis suggests, based on very low certainty evidence, that MRI-TPB has better detection for clinically significant prostate cancer, anterior tumors, and lower complications.
引用
- Rai BP, Mayerhofer C, Somani BK, et al. Magnetic Resonance Imaging/Ultrasound Fusion-guided Transperineal Versus Magnetic Resonance Imaging/Ultrasound Fusion-guided Transrectal Prostate Biopsy-A Systematic Review. Eur Urol Oncol. 2021. PMID: 33478936. doi:10.1016/j.euo.2020.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。